Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Over-the-Counter Drugs Market is predicted to reach US$ by 2030 from US$ 169.1 billion in 2021, and to grow at a CAGR of 5.3% between the forecast period 2022 to 2030.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2022 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2021. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
By Products (Analgesics & Pain Relievers, Cough, Cold & Flu Products, Vitamin & Mineral Supplements, Gastrointestinal Products, Dermatological Products, Ophthalmic Products, Sleep Aids, Weight Loss/Dietary Supplements, and Smoking Cessation Aids and Others) Distribution Channels (Drug Stores & Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
Johnson & Johnson, Novartis AG, Teva pharmaceuticals, GlaxoSmithKline plc, Bayer AG, PGT healthcare, Pfizer Inc., Boehringer Ingelheim, Merck KGaA, Reckitt Benckiser Group PLC., Glenmark Pharmaceuticals Ltd., Sanofi-Aventis U.S. LLC, and Takeda Pharmaceutical Company Limited, among others